SK16242000A3 - Fenylsulfónamid-fenyletylamíny užitočné ako dopamínové receptory - Google Patents
Fenylsulfónamid-fenyletylamíny užitočné ako dopamínové receptory Download PDFInfo
- Publication number
- SK16242000A3 SK16242000A3 SK1624-2000A SK16242000A SK16242000A3 SK 16242000 A3 SK16242000 A3 SK 16242000A3 SK 16242000 A SK16242000 A SK 16242000A SK 16242000 A3 SK16242000 A3 SK 16242000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- ethyl
- propylamine
- phenyl
- alkyl
- compound
- Prior art date
Links
- GNLBKOISUOPBOL-UHFFFAOYSA-N benzenesulfonamide;2-phenylethanamine Chemical class NCCC1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 GNLBKOISUOPBOL-UHFFFAOYSA-N 0.000 title description 2
- 102000015554 Dopamine receptor Human genes 0.000 title 1
- 108050004812 Dopamine receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- 102000004073 Dopamine D3 Receptors Human genes 0.000 claims abstract description 7
- 108090000525 Dopamine D3 Receptors Proteins 0.000 claims abstract description 7
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 7
- 150000002367 halogens Chemical class 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 3
- 208000015114 central nervous system disease Diseases 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 26
- -1 4-Chlorobenzenesulfonamido Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- GCWGADZVRFZLBG-UHFFFAOYSA-N tert-butyl 2-[2-(4-aminophenyl)ethylamino]butanoate Chemical compound CC(C)(C)OC(=O)C(CC)NCCC1=CC=C(N)C=C1 GCWGADZVRFZLBG-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- YYOHEGJBKTVTLK-UHFFFAOYSA-N 2,4-dichloro-n-[4-[2-(propylamino)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(CCNCCC)=CC=C1NS(=O)(=O)C1=CC=C(Cl)C=C1Cl YYOHEGJBKTVTLK-UHFFFAOYSA-N 0.000 claims description 4
- DOFFSUIUWSPOJI-UHFFFAOYSA-N 2-chloro-4-fluoro-n-[4-[2-(propylamino)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(CCNCCC)=CC=C1NS(=O)(=O)C1=CC=C(F)C=C1Cl DOFFSUIUWSPOJI-UHFFFAOYSA-N 0.000 claims description 4
- XUAUSHRTHCVYEJ-UHFFFAOYSA-N 2-fluoro-n-[3-[2-(propylamino)ethyl]phenyl]benzenesulfonamide Chemical compound CCCNCCC1=CC=CC(NS(=O)(=O)C=2C(=CC=CC=2)F)=C1 XUAUSHRTHCVYEJ-UHFFFAOYSA-N 0.000 claims description 4
- GYCXCBYOHASGSD-UHFFFAOYSA-N 3-chloro-n-[3-[2-(propylamino)ethyl]phenyl]benzenesulfonamide Chemical compound CCCNCCC1=CC=CC(NS(=O)(=O)C=2C=C(Cl)C=CC=2)=C1 GYCXCBYOHASGSD-UHFFFAOYSA-N 0.000 claims description 4
- GLBXYJLKQWSMHH-UHFFFAOYSA-N 4-bromo-n-[4-[2-(propylamino)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(CCNCCC)=CC=C1NS(=O)(=O)C1=CC=C(Br)C=C1 GLBXYJLKQWSMHH-UHFFFAOYSA-N 0.000 claims description 4
- VCHHCUQGXMWXAM-UHFFFAOYSA-N 4-chloro-n-[4-[2-(propylamino)ethyl]phenyl]benzenesulfonamide Chemical compound C1=CC(CCNCCC)=CC=C1NS(=O)(=O)C1=CC=C(Cl)C=C1 VCHHCUQGXMWXAM-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 claims 2
- JGGQWSXZZQPZTR-UHFFFAOYSA-N n-[4-[2-(propylamino)ethyl]phenyl]-4-(trifluoromethoxy)benzenesulfonamide Chemical compound C1=CC(CCNCCC)=CC=C1NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 JGGQWSXZZQPZTR-UHFFFAOYSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical class CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 201000000980 schizophrenia Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 208000011117 substance-related disease Diseases 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 150000004982 aromatic amines Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 2
- JVMHULJEYUQYSH-UHFFFAOYSA-N 2-(4-nitrophenyl)ethylazanium;chloride Chemical compound Cl.NCCC1=CC=C([N+]([O-])=O)C=C1 JVMHULJEYUQYSH-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- OOKNVVKYQLZQDC-UHFFFAOYSA-N n-[4-[2-(propylamino)ethyl]phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=CC(CCNCCC)=CC=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 OOKNVVKYQLZQDC-UHFFFAOYSA-N 0.000 description 2
- PAZVJIOFFOOQLQ-UHFFFAOYSA-N n-ethyl-n-propylaniline Chemical compound CCCN(CC)C1=CC=CC=C1 PAZVJIOFFOOQLQ-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- FDTPBIKNYWQLAE-UHFFFAOYSA-N 2,4-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 FDTPBIKNYWQLAE-UHFFFAOYSA-N 0.000 description 1
- KWHVBVJDKLSOTB-UHFFFAOYSA-N 2-(3-methylphenyl)ethanol Chemical compound CC1=CC=CC(CCO)=C1 KWHVBVJDKLSOTB-UHFFFAOYSA-N 0.000 description 1
- PWZWTSYUZQZFKE-UHFFFAOYSA-N 2-(3-nitrophenyl)ethanol Chemical compound OCCC1=CC=CC([N+]([O-])=O)=C1 PWZWTSYUZQZFKE-UHFFFAOYSA-N 0.000 description 1
- FCFPJKHVCHKCMP-UHFFFAOYSA-N 2-chloro-4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 FCFPJKHVCHKCMP-UHFFFAOYSA-N 0.000 description 1
- ZSZKAQCISWFDCQ-UHFFFAOYSA-N 2-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=CC=C1S(Cl)(=O)=O ZSZKAQCISWFDCQ-UHFFFAOYSA-N 0.000 description 1
- OINWZUJVEXUHCC-UHFFFAOYSA-N 3-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC(S(Cl)(=O)=O)=C1 OINWZUJVEXUHCC-UHFFFAOYSA-N 0.000 description 1
- UHCDBMIOLNKDHG-UHFFFAOYSA-N 4-(trifluoromethoxy)benzenesulfonyl chloride Chemical compound FC(F)(F)OC1=CC=C(S(Cl)(=O)=O)C=C1 UHCDBMIOLNKDHG-UHFFFAOYSA-N 0.000 description 1
- OZDCZHDOIBUGAJ-UHFFFAOYSA-N 4-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=C(S(Cl)(=O)=O)C=C1 OZDCZHDOIBUGAJ-UHFFFAOYSA-N 0.000 description 1
- GPKATEXWKFZQRH-UHFFFAOYSA-N 4-[2-(dipropylamino)ethyl]aniline Chemical compound CCCN(CCC)CCC1=CC=C(N)C=C1 GPKATEXWKFZQRH-UHFFFAOYSA-N 0.000 description 1
- GRDXCFKBQWDAJH-UHFFFAOYSA-N 4-acetamidobenzenesulfonyl chloride Chemical compound CC(=O)NC1=CC=C(S(Cl)(=O)=O)C=C1 GRDXCFKBQWDAJH-UHFFFAOYSA-N 0.000 description 1
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- IYHSCCCNULJSLJ-UHFFFAOYSA-N tert-butyl 2-(ethylamino)butanoate Chemical compound CCNC(CC)C(=O)OC(C)(C)C IYHSCCCNULJSLJ-UHFFFAOYSA-N 0.000 description 1
- UOQRWBOYRPYPAN-UHFFFAOYSA-N tert-butyl 2-[2-(3-aminophenyl)ethylamino]butanoate Chemical compound CC(C)(C)OC(=O)C(CC)NCCC1=CC=CC(N)=C1 UOQRWBOYRPYPAN-UHFFFAOYSA-N 0.000 description 1
- UIYOVVYZPVVUMJ-UHFFFAOYSA-N tert-butyl carbamoyl carbonate Chemical compound CC(C)(C)OC(=O)OC(N)=O UIYOVVYZPVVUMJ-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8549398P | 1998-05-14 | 1998-05-14 | |
| PCT/US1999/007023 WO1999058499A1 (en) | 1998-05-14 | 1999-05-07 | Phenylsulfonamide-phenylethylamines useful as dopamine receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK16242000A3 true SK16242000A3 (sk) | 2001-06-11 |
Family
ID=22191975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1624-2000A SK16242000A3 (sk) | 1998-05-14 | 1999-05-07 | Fenylsulfónamid-fenyletylamíny užitočné ako dopamínové receptory |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6103766A (zh) |
| EP (1) | EP1077935B1 (zh) |
| JP (1) | JP2002514623A (zh) |
| KR (1) | KR20010043546A (zh) |
| CN (1) | CN1152857C (zh) |
| AT (1) | ATE253045T1 (zh) |
| AU (1) | AU752543B2 (zh) |
| BR (1) | BR9910405A (zh) |
| CA (1) | CA2327345A1 (zh) |
| DE (1) | DE69912419T2 (zh) |
| DK (1) | DK1077935T3 (zh) |
| EA (1) | EA002918B1 (zh) |
| ES (1) | ES2211078T3 (zh) |
| HK (1) | HK1036049A1 (zh) |
| HU (1) | HUP0101746A3 (zh) |
| IL (1) | IL139263A0 (zh) |
| NO (1) | NO20005732L (zh) |
| NZ (1) | NZ508152A (zh) |
| PL (1) | PL343891A1 (zh) |
| PT (1) | PT1077935E (zh) |
| SK (1) | SK16242000A3 (zh) |
| TR (1) | TR200003325T2 (zh) |
| TW (1) | TW450954B (zh) |
| WO (1) | WO1999058499A1 (zh) |
| ZA (1) | ZA200005921B (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT971878E (pt) * | 1997-02-27 | 2008-07-08 | Takeda Pharmaceutical | Compostos de amina, sua produção e utilização como inibidores da produção de amilóide beta |
| JP2004535390A (ja) * | 2001-05-07 | 2004-11-25 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| US20050043536A1 (en) * | 2001-05-07 | 2005-02-24 | Dashyant Dhanak | Sulfonamides |
| WO2006040179A1 (en) * | 2004-10-14 | 2006-04-20 | Abbott Gmbh & Co. Kg | Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| WO2006040182A1 (en) | 2004-10-14 | 2006-04-20 | Abbott Gmbh & Co. Kg | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| WO2006040176A1 (en) | 2004-10-14 | 2006-04-20 | Abbott Gmbh & Co. Kg | Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| EP2013179B1 (en) | 2006-04-14 | 2011-01-19 | Abbott GmbH & Co. KG | Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| ES2360254T3 (es) * | 2006-04-14 | 2011-06-02 | ABBOTT GMBH & CO. KG | Compuestos de ariloxietilamina adecuados para tratamiento de trastornos que respondan a la modulación del receptor de dopamina d3. |
| US8642642B2 (en) | 2006-04-19 | 2014-02-04 | Abbott Laboratories | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor |
| TW200808762A (en) | 2006-04-19 | 2008-02-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor |
| WO2008026046A1 (en) * | 2006-08-30 | 2008-03-06 | Pfizer Products Inc. | Morpholine d3 dopamine antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3574741A (en) * | 1969-04-14 | 1971-04-13 | Mead Johnson & Co | Sulfonamidophenalkylamines |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| GB9402197D0 (en) * | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Compounds |
| AU4368996A (en) * | 1994-11-23 | 1996-06-17 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| ATE232850T1 (de) * | 1996-05-11 | 2003-03-15 | Smithkline Beecham Plc | Tetrahydroisoquinoline derivate als modulatoren von dopamine d3 rezeptoren |
| DE69734215T2 (de) * | 1996-07-22 | 2006-06-29 | Novo Nordisk A/S | Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften |
| JPH1180156A (ja) * | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体 |
-
1999
- 1999-04-26 TW TW088106644A patent/TW450954B/zh not_active IP Right Cessation
- 1999-05-07 KR KR1020007012661A patent/KR20010043546A/ko active IP Right Grant
- 1999-05-07 AU AU37418/99A patent/AU752543B2/en not_active Ceased
- 1999-05-07 NZ NZ508152A patent/NZ508152A/xx unknown
- 1999-05-07 HU HU0101746A patent/HUP0101746A3/hu unknown
- 1999-05-07 EP EP99919771A patent/EP1077935B1/en not_active Expired - Lifetime
- 1999-05-07 TR TR2000/03325T patent/TR200003325T2/xx unknown
- 1999-05-07 CN CNB998052175A patent/CN1152857C/zh not_active Expired - Fee Related
- 1999-05-07 EA EA200001184A patent/EA002918B1/ru not_active IP Right Cessation
- 1999-05-07 CA CA002327345A patent/CA2327345A1/en not_active Abandoned
- 1999-05-07 DE DE69912419T patent/DE69912419T2/de not_active Expired - Fee Related
- 1999-05-07 DK DK99919771T patent/DK1077935T3/da active
- 1999-05-07 PL PL99343891A patent/PL343891A1/xx unknown
- 1999-05-07 JP JP2000548303A patent/JP2002514623A/ja not_active Withdrawn
- 1999-05-07 IL IL13926399A patent/IL139263A0/xx not_active IP Right Cessation
- 1999-05-07 PT PT99919771T patent/PT1077935E/pt unknown
- 1999-05-07 BR BR9910405-9A patent/BR9910405A/pt not_active Application Discontinuation
- 1999-05-07 SK SK1624-2000A patent/SK16242000A3/sk unknown
- 1999-05-07 AT AT99919771T patent/ATE253045T1/de not_active IP Right Cessation
- 1999-05-07 WO PCT/US1999/007023 patent/WO1999058499A1/en active IP Right Grant
- 1999-05-07 US US09/306,748 patent/US6103766A/en not_active Expired - Fee Related
- 1999-05-07 ES ES99919771T patent/ES2211078T3/es not_active Expired - Lifetime
-
2000
- 2000-10-23 ZA ZA200005921A patent/ZA200005921B/en unknown
- 2000-11-13 NO NO20005732A patent/NO20005732L/no not_active Application Discontinuation
-
2001
- 2001-09-20 HK HK01106645A patent/HK1036049A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69912419T2 (de) | 2004-07-22 |
| US6103766A (en) | 2000-08-15 |
| AU3741899A (en) | 1999-11-29 |
| BR9910405A (pt) | 2001-01-09 |
| NO20005732D0 (no) | 2000-11-13 |
| JP2002514623A (ja) | 2002-05-21 |
| CN1297431A (zh) | 2001-05-30 |
| CA2327345A1 (en) | 1999-11-18 |
| PT1077935E (pt) | 2004-03-31 |
| NO20005732L (no) | 2000-11-13 |
| EP1077935A1 (en) | 2001-02-28 |
| KR20010043546A (ko) | 2001-05-25 |
| HUP0101746A2 (hu) | 2002-03-28 |
| HK1036049A1 (en) | 2001-12-21 |
| AU752543B2 (en) | 2002-09-19 |
| CN1152857C (zh) | 2004-06-09 |
| HUP0101746A3 (en) | 2002-10-28 |
| DK1077935T3 (da) | 2004-02-16 |
| EP1077935B1 (en) | 2003-10-29 |
| ZA200005921B (en) | 2001-11-14 |
| DE69912419D1 (de) | 2003-12-04 |
| PL343891A1 (en) | 2001-09-10 |
| TW450954B (en) | 2001-08-21 |
| ES2211078T3 (es) | 2004-07-01 |
| ATE253045T1 (de) | 2003-11-15 |
| IL139263A0 (en) | 2001-11-25 |
| TR200003325T2 (tr) | 2001-04-20 |
| NZ508152A (en) | 2003-03-28 |
| EA002918B1 (ru) | 2002-10-31 |
| WO1999058499A1 (en) | 1999-11-18 |
| EA200001184A1 (ru) | 2001-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2089547C1 (ru) | Производные n-алкиленпиперидина, способ их получения, фармацевтическая композиция на их основе, оптически чистые производные n-алкиленпиперидина | |
| AU657272B2 (en) | Arylalkylamines, process for preparing them and pharmaceutical compositions containing them | |
| PL166582B1 (pl) | Sposób wytwarzania nowych pochodnych amin aromatycznych PL PL | |
| AU2005225632B2 (en) | Formamide derivatives useful as adrenoceptor | |
| PT763031E (pt) | Derivados da piperazina como antagonistas 5ht1a | |
| DE3700408A1 (de) | Indolderivate, sie enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung | |
| PL210131B1 (pl) | Pochodne sulfonoamidowe, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie tych pochodnych | |
| CZ285409B6 (cs) | Polycyklické aminosloučeniny a jejich enantiomery, způsob jejich přípravy a farmaceutické prostředky, které je obsahují | |
| CA2378499A1 (en) | Cyclic amine ccr3 antagonists | |
| JPS60239458A (ja) | 新規化合物およびそれを含有する抗不整脈剤医薬組成物 | |
| SK16242000A3 (sk) | Fenylsulfónamid-fenyletylamíny užitočné ako dopamínové receptory | |
| US20070099986A1 (en) | Preventives/remedies for urinary disturbance | |
| PL165842B1 (pl) | Sposób wytwarzania nowych pochodnych heksahydroazepiny PL PL PL PL PL PL | |
| KR20030024919A (ko) | Ｎ-(3,5-디클로로-2-메톡시페닐)-4-메톡시-3-피페라진-1-일-벤젠술폰아미드 | |
| US4652584A (en) | Acetylenic phenoxypropanol derivatives and pharmaceutical compositions for the treatment of hypertension | |
| EP0443862A1 (en) | Triamine derivatives and their acid-addition salts | |
| NO882065L (no) | Diarylalkyl-substituerte alkylaminer, fremgangsmaate for fremstilling av dem, anvendelse av dem, saavel som legemidler som inneholder dem. | |
| SK6522003A3 (en) | Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same | |
| CZ20004173A3 (cs) | Fenylsulfonamid-fenylethylaminy užitečné jako dopaminové receptory | |
| JPS624250A (ja) | ベンズ三置換−２−アミノテトラリン | |
| MXPA00011147A (en) | Phenylsulfonamide-phenylethylamines useful as dopamine receptors | |
| JPH0616638A (ja) | ピリジン化合物およびその医薬用途 | |
| FR2663329A1 (fr) | Composes aromatiques amines, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| JP2005523936A (ja) | タムスロシン誘導体 | |
| FR2654100A1 (fr) | Arylalkylenediamines, procede pour leur preparation et compositions pharmaceutiques les contenant. |